Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
NCT03703882 is registered in ClinicalTrials.gov with Catabasis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
- Lead sponsor
- Catabasis Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 2, 2018
- Completion date
- September 22, 2020
- Enrollment
- 131 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.